Revvity launches EONIS Q system enabling faster, simplified newborn screening for SMA and SCID

Nov. 27, 2023
Molecular diagnostics workflow reduces complexity and costs for labs looking to expand newborn screening capabilities.

Revvity, Inc., announced the launch of its EONIS Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns. 

The EONIS Q system simplifies and streamlines molecular testing for SMA and SCID with an innovative workflow, inclusive of the EONIS Q96 instrument, the EONIS SCID-SMA kit and dedicated EONIS EASI software. 

Turnaround time for the EONIS Q workflow from sample-in to result is approximately three hours. There are no wash steps required and fewer pipetting and centrifuging steps involved, further reducing hands-on time. Compared to other methods, the EONIS Q system uses fewer consumables and one-time use plasticware.

Revvity release